Evaxion Biotech A/S Stock Analysis & AI Score
Evaxion Biotech A/S (EVAX) has an ST Score of 57.0 (B-), driven by its Growth (A+) and held back by its Financial Strength (D+). Analysts rate it Buy with a $11.67 price target (+258.0% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Evaxion Biotech A/S (EVAX) has an ST Score of 57.0 (B-), driven by its Growth (A+) and held back by its Financial Strength (D+). Analysts rate it Buy with a $11.67 price target (+258.0% upside).
- Strongest
- GrowthA+
- Weakest
- Financial StrengthD+
All factor grades
- GrowthA+
- ForecastA
- MomentumB+
- ProfitabilityC
- ValuationD+
- Financial StrengthD+
- Piotroski5/9
Contact
EVAX stock: frequently asked questions
What is EVAX's ST Score?
Evaxion Biotech A/S (EVAX) has an ST Score of 57.0 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is EVAX a buy, hold, or sell?
Analysts rate EVAX a Buy, with a price target of $11.67 (+258.0% vs the current price). Our ST Score grades it B- (57.0/100). The ST Score is a data-driven signal, not a recommendation.
What are EVAX's factor grades?
Valuation D+, Profitability C, Financial Strength D+, Momentum B+, Growth A+, Forecast A.
What is EVAX's valuation grade?
Evaxion Biotech A/S (EVAX) earns a valuation grade of D+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is EVAX's growth grade?
Evaxion Biotech A/S (EVAX) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is EVAX's profitability grade?
Evaxion Biotech A/S (EVAX) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is EVAX's financial strength grade?
Evaxion Biotech A/S (EVAX) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for EVAX?
The average analyst price target for Evaxion Biotech A/S (EVAX) is $11.67 from 4 analysts, which is +258.0% versus the recent price of $3.26.
What is EVAX's Piotroski score?
Evaxion Biotech A/S (EVAX) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.